163 related articles for article (PubMed ID: 8200854)
1. Active efflux system for cisplatin in cisplatin-resistant human KB cells.
Fujii R; Mutoh M; Niwa K; Yamada K; Aikou T; Nakagawa M; Kuwano M; Akiyama S
Jpn J Cancer Res; 1994 Apr; 85(4):426-33. PubMed ID: 8200854
[TBL] [Abstract][Full Text] [Related]
2. Adenosine triphosphate-dependent transport of leukotriene C4 by membrane vesicles prepared from cisplatin-resistant human epidermoid carcinoma tumor cells.
Fujii R; Mutoh M; Sumizawa T; Chen ZS; Yoshimura A; Akiyama S
J Natl Cancer Inst; 1994 Dec; 86(23):1781-4. PubMed ID: 7966417
[TBL] [Abstract][Full Text] [Related]
3. An active efflux system for heavy metals in cisplatin-resistant human KB carcinoma cells.
Chen ZS; Mutoh M; Sumizawa T; Furukawa T; Haraguchi M; Tani A; Saijo N; Kondo T; Akiyama S
Exp Cell Res; 1998 May; 240(2):312-20. PubMed ID: 9597004
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the ATP-dependent LTC4 transporter in cisplatin-resistant human KB cells.
Chuman Y; Chen ZS; Sumizawa T; Furukawa T; Haraguchi M; Takebayashi Y; Niwa K; Yamada K; Aikou T; Akiyama S
Biochem Biophys Res Commun; 1996 Sep; 226(1):158-65. PubMed ID: 8806607
[TBL] [Abstract][Full Text] [Related]
5. Involvement of NF-κB activation in the cisplatin resistance of human epidermoid carcinoma KCP-4 cells.
Oiso S; Ikeda R; Nakamura K; Takeda Y; Akiyama S; Kariyazono H
Oncol Rep; 2012 Jul; 28(1):27-32. PubMed ID: 22562377
[TBL] [Abstract][Full Text] [Related]
6. Factors involved in the cisplatin resistance of KCP‑4 human epidermoid carcinoma cells.
Oiso S; Takayama Y; Nakazaki R; Matsunaga N; Motooka C; Yamamura A; Ikeda R; Nakamura K; Takeda Y; Kariyazono H
Oncol Rep; 2014 Feb; 31(2):719-26. PubMed ID: 24317338
[TBL] [Abstract][Full Text] [Related]
7. Enhanced nucleotide excision repair in cisplatin resistant human KB carcinoma cells.
Mukai M; Kanzaki A; Chen ZS; Miyashita H; Sumizawa T; Furukawa T; Haraguchi M; Takebayashi Y; Takamatsu H; Akiyama S
Oncol Rep; 2002; 9(4):839-44. PubMed ID: 12066219
[TBL] [Abstract][Full Text] [Related]
8. An enhanced active efflux of CPT-11 and SN-38 in cisplatin-resistant human KB carcinoma cells.
Chen ZS; Sumizawa T; Furukawa T; Ono K; Tani A; Komatsu M; Akiyama S
Cancer Lett; 1999 Apr; 138(1-2):13-22. PubMed ID: 10378768
[TBL] [Abstract][Full Text] [Related]
9. Differences in substrate specificity among glutathione conjugates (GS-X) pump family members: comparison between multidrug resistance-associated protein and a novel transporter expressed on a cisplatin-resistant cell line (KCP-4).
Ueda K; Suzuki H; Akiyama S; Sugiyama Y
Jpn J Cancer Res; 1999 Apr; 90(4):439-47. PubMed ID: 10363583
[TBL] [Abstract][Full Text] [Related]
10. Ascorbic acid increases drug accumulation and reverses vincristine resistance of human non-small-cell lung-cancer cells.
Chiang CD; Song EJ; Yang VC; Chao CC
Biochem J; 1994 Aug; 301 ( Pt 3)(Pt 3):759-64. PubMed ID: 7914401
[TBL] [Abstract][Full Text] [Related]
11. Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance.
Komatsu M; Sumizawa T; Mutoh M; Chen ZS; Terada K; Furukawa T; Yang XL; Gao H; Miura N; Sugiyama T; Akiyama S
Cancer Res; 2000 Mar; 60(5):1312-6. PubMed ID: 10728692
[TBL] [Abstract][Full Text] [Related]
12. Increased efflux of vincristine, but not of daunorubicin, associated with the murine multidrug resistance protein (MRP).
Slapak CA; Martell RL; Terashima M; Levy SB
Biochem Pharmacol; 1996 Nov; 52(10):1569-76. PubMed ID: 8937472
[TBL] [Abstract][Full Text] [Related]
13. The mechanism of the difference in cellular uptake of platinum derivatives in non-small cell lung cancer cell line (PC-14) and its cisplatin-resistant subline (PC-14/CDDP).
Ohmori T; Morikage T; Sugimoto Y; Fujiwara Y; Kasahara K; Nishio K; Ohta S; Sasaki Y; Takahashi T; Saijo N
Jpn J Cancer Res; 1993 Jan; 84(1):83-92. PubMed ID: 8383649
[TBL] [Abstract][Full Text] [Related]
14. In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines.
Ohe Y; Nakagawa K; Fujiwara Y; Sasaki Y; Minato K; Bungo M; Niimi S; Horichi N; Fukuda M; Saijo N
Cancer Res; 1989 Aug; 49(15):4098-102. PubMed ID: 2472873
[TBL] [Abstract][Full Text] [Related]
15. Cross-resistance to cis-diamminedichloroplatinum(II) of a multidrug-resistant lymphoma cell line associated with decreased drug accumulation and enhanced DNA repair.
Chao CC
Eur J Pharmacol; 1996 Jun; 305(1-3):213-22. PubMed ID: 8813556
[TBL] [Abstract][Full Text] [Related]
16. Decreased accumulation of [14C]carboplatin in human cisplatin-resistant cells results from reduced energy-dependent uptake.
Shen DW; Goldenberg S; Pastan I; Gottesman MM
J Cell Physiol; 2000 Apr; 183(1):108-16. PubMed ID: 10699972
[TBL] [Abstract][Full Text] [Related]
17. Alterations in the glycoform of cisplatin-resistant human carcinoma cells are caused by defects in the endoplasmic reticulum-associated degradation system.
Nakagawa H; Ohira M; Hayashi S; Abe S; Saito S; Nagahori N; Monde K; Shinohara Y; Fujitani N; Kondo H; Akiyama S; Nakagawara A; Nishimura S
Cancer Lett; 2008 Nov; 270(2):295-301. PubMed ID: 18573595
[TBL] [Abstract][Full Text] [Related]
18. cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells.
Andrews PA; Velury S; Mann SC; Howell SB
Cancer Res; 1988 Jan; 48(1):68-73. PubMed ID: 3335000
[TBL] [Abstract][Full Text] [Related]
19. Changes in biophysical parameters of plasma membranes influence cisplatin resistance of sensitive and resistant epidermal carcinoma cells.
Liang XJ; Yin JJ; Zhou JW; Wang PC; Taylor B; Cardarelli C; Kozar M; Forte R; Aszalos A; Gottesman MM
Exp Cell Res; 2004 Feb; 293(2):283-91. PubMed ID: 14729466
[TBL] [Abstract][Full Text] [Related]
20. Codominance of cisplatin resistance in somatic cell hybrids.
Ying YL; Shen DW; Liang XJ; Gottesman MM
J Cell Physiol; 2003 Jul; 196(1):63-9. PubMed ID: 12767041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
